TP53 Mutation Analysis in MDS: Comparing Sequencing Technologies

Myelodysplastic syndromes (MDS) represent a complex group of bone marrow disorders requiring precise genomic evaluation. Because genetic markers influence therapeutic choices, TP53 mutation analysis has become a standard requirement in clinical hematology. Currently, most diagnostic centers rely on short-read sequencing (SRS) to identify these critical mutations. However, SRS platforms often struggle to provide a complete picture of the genetic landscape. Consequently, medical experts are increasingly looking toward long-read sequencing (LRS) to resolve these diagnostic gaps.

The primary challenge in MDS involves distinguishing between monoallelic and biallelic TP53 alterations. Recent data suggests that only the "multi-hit" or biallelic state confers a truly dismal prognosis. Short-read platforms frequently fail to determine whether two different mutations occur on the same chromosome or separate ones. In contrast, long-read sequencing allows for direct phasing of variants. This technology provides clarity by spanning large genomic regions in a single read. Furthermore, LRS improves the detection of complex structural variations and large deletions that often accompany TP53 dysfunction.

Clinical Benefits of TP53 Mutation Analysis

Accurate TP53 mutation analysis significantly impacts risk stratification and transplant eligibility. For example, patients with a single-hit mutation may achieve outcomes similar to wild-type cases. Therefore, identifying these patients helps avoid overly aggressive treatments. Additionally, long-read technologies help clinicians monitor clonal evolution during follow-up. Because TP53-mutant clones often drive disease progression, early detection of these changes is vital. Similarly, modern sequencing methods allow for better identification of germline predispositions, such as Li-Fraumeni syndrome. In conclusion, while SRS remains the current workhorse, the transition to LRS could revolutionize how we manage high-risk MDS.

Frequently Asked Questions

Why is TP53 mutation analysis essential for MDS patients?

It provides critical prognostic information. Specifically, it identifies multi-hit states that signify high resistance to standard treatments and a greater risk of leukemic transformation.

How does long-read sequencing differ from short-read sequencing in MDS?

Long-read sequencing can phase mutations and detect large structural variants. This allows doctors to distinguish between single-copy loss and complex biallelic inactivation more accurately than short-read methods.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Mittelman M et al. TP53 mutation analysis in myelodysplastic syndromes - long or short read sequencing? Haematologica. 2026 Apr 16. doi: 10.3324/haematol.2026.300932. PMID: 41988775.


2. Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability and clinical outcomes in myelodysplastic syndromes. Nat Genet. 2020;52(12):1319-1327.


3. Sallman DA. The Clinical Impact of TP53 Mutations in Myeloid Malignancies. Hematology Am Soc Hematol Educ Program. 2022;2022(1):475-481.